Two immunotherapy drugs for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests two new immunotherapy drugs (JS207 and JS007) as a first treatment for advanced liver cancer. It might be an option if you have not had any prior cancer medicine and your liver tumor is not blocking the main portal vein.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (HCC) that cannot be removed by surgery or treated with local procedures like ablation or chemoembolization.
- You have not received any systemic anti-cancer drugs (like chemotherapy, targeted therapy, or immunotherapy) for your liver cancer before.
- You have at least one tumor that can be measured on a scan (CT or MRI) and that has grown if previously treated locally.
- Your liver function is relatively good (Child-Pugh class A or B with a score of 7 or less, and no history of hepatic encephalopathy).
- You are in generally good health (able to perform daily activities without help) and your life expectancy is at least 3 months.
- You do not have major health issues like uncontrolled infections, severe heart disease, recent bleeding, or active autoimmune disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This study is testing whether combining targeted therapy with immunotherapy can help people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination treatment is safe and effective.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.